MDM2 and cancer: Comparing trajectories for PTEN-cancer cells for monotherapy (Fig. 2C) with these for combination therapy (Fig. 4C) we may notice that Mdm2 inhibitor administration leads to an increase of p53killer oscillation amplitude.